NDRG1 调节铁代谢并抑制病态心脏缩
Jiali Yuan1, Chengye Yin1, Hong Peng1
1Department of Cardiology, Xinhua Hospital, Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
The Canadian journal of cardiology
|October 20, 2024
概括
N-myc下游调节基因1 (NDRG1) 通过调节铁代谢和铁亡,在预防心脏缩方面发挥着至关重要的作用. 失去NDRG1会加剧心力衰竭,而过度表达则会提供保护.
科学领域:
- 心血管生物学 心血管生物学
- 细胞生物学 细胞生物学
- 分子医学是分子医学.
背景情况:
- 病理性心脏缩是心力衰竭的先驱,潜在的细胞机制尚未完全理解.
- N-myc下游调节基因1 (NDRG1) 与细胞压力有关,但其在心脏病中的作用尚不清楚.
- 这项研究研究了NDRG1在病理性心脏缩中的功能.
研究的目的:
- 阐明NDRG1在心脏缩的发展中的作用.
- 确定NDRG1影响心肌细胞功能的分子机制.
- 探索NDRG1作为心脏缩的潜在治疗点.
主要方法:
- 使用心肌细胞特异性NDRG1淘汰小鼠和AAV9介导的过度表达.
- 使用 ангиотензин II (AngII) 刺激诱导的心脏缩.
- 进行了组织学,分子,RNA测序,铁和铁水平分析,包括共免疫沉和铁化.
主要成果:
- 在AngII诱导的心脏缩中,NDRG1表达减少.
- 缺少NDRG1导致了渐进的心脏缩,心力衰竭,铁过载和铁.
- 过度表达NDRG1可以逆转AngII诱导的缩和纤维化,NDRG1与转激素相互作用,调节铁代谢.
结论:
- 在心肌细胞中,NDRG1对于调节铁代谢和铁的作用至关重要.
- 由于铁的失调,NDRG1缺乏会促进心脏缩和心力衰竭.
- NDRG1和铁代谢途径代表了心脏缩的潜在治疗标.
更多相关视频
相关概念视频
Cardiomyopathy IV: Restrictive Cardiomyopathy
1
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
1
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Heart Failure Drugs: Inotropic Agents
527
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
527
Heart Failure II: Pathophysiology
1
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...


